Peptides for tumour therapy and diagnosis: Current status and future directions

Current Medicinal Chemistry

Volumn 16, Issue 7, 2009, Pages 780-795

  Zaccaro, Laura ^a   del Gatto, Annarita ^a   Pedone, Carlo ^a   Saviano, Michele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CCK; Integrin; Somatostatin; Structure activity relationships; Tumour diseases

Indexed keywords

4 [[5 (8 AZASPIRO[4.5]DECAN 8 YL) 4 [(3,5 DICHLOROBENZOYL)AMINO] 5 OXOPENTANOYL]AMINO] 5 (1 NAPHTHYLAMINO) 5 OXOPENTANOIC ACID; ANGIOPEPTIN; ARGINYLGLYCYLASPARTIC ACID; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CILENGITIDE; CR 2345; CR 2767; DEPREOTIDE TC 99M; INTEGRIN; INTEGRIN RECEPTOR; ITRIGLUMIDE; LORGLUMIDE; LOXIGLUMIDE; NC 100692 TECHNETIUM TC 99M; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; OCTREOTIDE; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90]; PASIREOTIDE; PENTETREOTIDE IN 111; PROGLUMIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SPIROGLUMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

ACROMEGALY; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CARCINOID; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GASTRINOMA; GASTROINTESTINAL TUMOR; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA;

AMINO ACID SEQUENCE; ANIMALS; CHOLECYSTOKININ; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; RADIOPHARMACEUTICALS; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 65649117755     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787549307     Document Type: Review

References (191)

1. Okarvi, S. M. Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev., 2004, 24, 357-397.
2. Biron, E.; Chatterjee, J.; Ovadia, O.; Langenegger, D.; Brueggen, J.; Hoyer, D.; Schmid, H. A.; Jelinek, R.; Gilon, C.; Hoffman, A.; Kessler, H. Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew. Chem. Int. Ed. Eng., 2008, 47, 2595-2599.
3. Patel, Y. C. Somatostatin and its receptor family. Front. Neuroendocrinol., 1999, 20, 157-198.
4. Lewin, M. J. The somatostatin receptor in the GI tract. Annu. Rev. Physiol., 1992, 54, 455-468.
5. Bousquet, C.; Puente, E.; Buscail, L.; Vaysse, N.; Susini, C. Antiproliferative effect of somatostatin and analogs. Chemotherapy, 2001, 47 Suppl 2, 30-39.
6. Hu, C.; Yi, C.; Hao, Z.; Cao, S.; Li, H.; Shao, X.; Zhang, J.; Qiao, T.; Fan, D. Cancer Biol. Ther., 2004, 3, 726-730.
7. Bruno, J. F.; Xu, Y.; Song, J.; Berelowitz, M. Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc. Natl. Acad. Sci. USA, 1992, 89, 11151-11155
8. Meyerhof, W. The elucidation of somatostatin receptor functions: A current view. Rev. Physiol. Biochem. Pharmacol., 1998, 133, 55-108.
9. Reisine, T.; Bell, G. I. Molecular biology of somatostatin receptors. Endocr. Rev. 1995, 16, 427-442.
10. Vanetti, M.; Kouba, M.; Wang, X.; Vogt, G.; Hollt, V. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett., 1992, 311, 290-294.
11. Vanetti, M.; Vogt, G.; Hollt, V. The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization. FEBS Lett., 1993, 331, 260-266
12. Rocheville, M.; Lange, D. C.; Kumar, U.; Sasi, R.; Patel, R. C.; Patel, Y. C. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem., 2000, 275, 7862-7869.
13. Pfeiffer, M.; Koch, T.; Schroder, H.; Klutzny, M.; Kirscht, S.; Kreienkamp, H. J.; Hollt, V.; Schulz, S. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem., 2001, 276, 14027-14036.
14. Rens-Domiano, S.; Reisine, T. Biochemical and functional properties of somatostatin receptors. J. Neurochem., 1992, 58, 1987-1996.
15. Schweitzer, P.; Madamba, S.; Siggins, G. R. Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal M-current. Nature, 1990, 346, 464-467.
16. Colas, B.; Cambillau, C.; Buscail, L.; Zeggari, M.; Esteve, J. P. et al. Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur. J. Biochem., 1992, 207, 1017-1024.
17. Pyronnet, S.; Bousquet, C.; Najib, S.; Azar, R.; Laklai, H. et al. Antitumor effects of somatostatin. Mol. Cell. Endocrinol., 2008, 286, 230-237.
18. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H. A.; Hoyer, D. et al. Opportunities in somatostatin research: Biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov., 2003, 2, 999-1017.
19. Oberg, K. Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment. Curr. Opin. Oncol., 2005, 17, 386-391.
20. Solcia, E.; Kloppel, G.; Sobin, H. Histological typing of endocrine tumors. World Health Organization International Histological Classification of Tumors. 2000.
21. Volante, M.; Rosas, R.; Allia, E.; Granata, R.; Baragli, A.; Muccioli, G.; Papotti, M. Somatostatin, cortistatin and their receptors in tumours. Mol. Cell Endocrinol., 2008, 286, 219-229.
22. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrinol. Rev., 2003, 24, 389-427
23. Hofland, L. J.; Lamberts, S. W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrinol. Rev., 2003, 24, 28-47.
24. de Herder, W. W.; Hofland, L. J.; van der Lely, A. J.; Lamberts, S. W. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocrinol. Relat. Cancer, 2003, 10, 451-458.
25. Bauer, W.; Briner, U.; Doepfner, W.; Haller, R.; Huguenin, R. et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci., 1982, 31, 1133-1140.
26. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 2006, 17, 1733-1742.
27. Bruns, C.; Lewis, I.; Briner, U.; Meno-Tetang, G.; Weckbecker, G. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol., 2002, 146, 707-716.
28. Weckbecker, G.; Briner, U.; Lewis, I.; Bruns, C. SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology, 2002, 143, 4123-4130.
29. van der Hoek, J.; van der Lelij, A. J.; Feelders, R. A.; de Herder, W. W.; Uitterlinden, P.; Poon, K. W.; Boerlin, V.; Lewis, I.; Krahnke, T.; Hofland, L. J.; Lamberts, S. W. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin. Endocrinol. (Oxf), 2005, 63, 176-184.
30. Schmid, H. A. Development, mechanism of action and potential applications. Mol. Cell Endocrinol., 2008, 286, 69-74.
31. Schmid, H. A.; Schoeffter, P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology, 2004, 80 Suppl 1, 47-50.
32. Valkema, R.; De Jong, M.; Bakker, W. H.; Breeman, W. A.; Kooij, P. P.; Lugtenburg, P. J.; De Jong, F. H.; Christiansen, A.; Kam, B. L.; De Herder, W. W.; Stridsberg, M.; Lindemans, J.; Ensing, G.; Krenning, E. P. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin. Nucl. Med., 2002, 32, 110-122.
33. McCarthy, K. E.; Woltering, E. A.; Anthony, L. B. In situ radiotherapy with 111In-pentetreotide. Q. J. Nucl. Med., 2000, 44, 88-95.
34. Anthony, L. B.; Woltering, E. A.; Espenan, G. D.; Cronin, M. D.; Maloney, T. J.; McCarthy, K. E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin. Nucl. Med., 2002, 32, 123-132.
35. Buscombe, J. R.; Caplin, M. E.; Hilson, A. J. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med., 2003, 44, 1-6.
36. Slooter, G. D.; Breeman, W. A.; Marquet, R. L.; Krenning, E. P.; van Eijck, C. H. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int. J. Cancer, 1999, 81, 767-771.
37. Reubi, J. C.; Schar, J. C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J. S.; Macke, H. R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27, 273-282.
38. Wild, D.; Schmitt, J. S.; Ginj, M.; Macke, H. R.; Bernard, B. F.; Krenning, E.; De Jong, M.; Wenger, S.; Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1338-1347.
39. Ginj, M.; Chen, J.; Walter, M. A.; Eltschinger, V.; Reubi, J. C.; Maecke, H. R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res., 2005, 11, 1136-1145.
40. Ginj, M.; Schmitt, J. S.; Chen, J.; Waser, B.; Reubi, J. C.; de Jong, M.; Schulz, S.; Maecke, H. R. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem. Biol., 2006, 13, 1081-1090.
41. O'Donoghue, J. A.; Bardies, M.; Wheldon, T. E. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J. Nucl. Med., 1995, 36, 1902-1909.
42. de Jong, M.; Breeman, W. A.; Valkema, R.; Bernard, B. F.; Krenning, E. P. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J. Nucl. Med., 2005, 46 Suppl 1, 13S-17S.
43. Iten, F.; Müller, B.; Schindler, C.; Rochlitz, C.; Oertli, D.; Mäcke, H. R.; Müller-Brand, J.; Walter, M. A. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial. Clin. Cancer Res., 2007, 13, 6696-6702.
44. Forrer, F.; Valkema, R.; Kwekkeboom, D. J.; de Jong, M.; Krenning, E. P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 111-129
45. Forrer, F.; Riedweg, I.; Maecke, H. R.; Mueller-Brand, J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q. J. Nucl. Med. Mol. Imaging, 2008, 52, 334-340.
46. Wehrmann, C.; Senftleben, S.; Zachert, C.; Muller, D.; Baum, R. P. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother. Radiopharm., 2007, 22, 406-416.
47. Kwekkeboom, D. J.; de Herder, W. W.; Kam, B. L.; van Eijck, C. H.; van Essen, M.; Kooij, P. P.; Feelders, R. A.; van Aken, M. O.; Krenning, E. P. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J. Clin. Oncol., 2008, 26, 2124-2130.
48. Davi, M. V.; Bodei, L.; Ferdeghini, M.; Falconi, M.; Testoni, M.; Paganelli, G.; Oliani, C.; Lo Cascio, V.; Francia, G. Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal. Endocr. Pract., 2008, 14, 213-218.
49. Raju, M. R.; Eisen, Y.; Carpenter, S.; Inkret, W. C. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat. Res., 1991, 128, 204-209.
50. Nikula, T. K.; McDevitt, M. R.; Finn, R. D.; Wu, C.; Kozak, R. W.; Garmestani, K.; Brechbiel, M. W.; Curcio, M. J.; Pippin, C. G.; Tiffany-Jones, L.; Geerlings, M. W., Sr.; Apostolidis, C.; Molinet, R.; Geerlings, M. W., Jr.; Gansow, O. A.; Scheinberg, D. A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176.
51. Miederer, M.; Henriksen, G.; Alke, A.; Mossbrugger, I.; Quintanilla-Martinez, L.; Senekowitsch-Schmidtke, R.; Essler, M. Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors. Clin. Cancer Res., 2008, 14, 3555-3561.
52. Ginj, M.; Zhang, H.; Waser, B.; Cescato, R.; Wild, D.; Wang, X.; Erchegyi, J.; Rivier, J.; Macke, H. R.; Reubi, J. C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA, 2006, 103, 16436-16441.
53. Janson, E.T.; Oberg, K. Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment. Cancer Chemother. Biol. Response Modif., 2003, 21, 535-546.
54. Gabriel, M.; Decristoforo, C.; Donnemiller, E.; Ulmer, H.; Watfah Rychlinski, C.; Mather, S. J.; Moncayo, R. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med., 2003, 44, 708-716.
55. Czepczynski, R.; Parisella, M. G.; Kosowicz, J.; Mikolajczak, R.; Ziemnicka, K.; Gryczynska, M.; Sowinski, J.; Signore, A. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1635-1645.
56. Cwikla, J. B.; Mikolajczak, R.; Pawlak, D.; Buscombe, J. R.; Nasierowska-Guttmejer, A.; Bator, A.; Maecke, H. R.; Walecki, J. Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs. J. Nucl. Med., 2008, 49, 1060-1065.
57. Vallabhajosula, S.; Moyer, B. R.; Lister-James, J.; McBride, B. J.; Lipszyc, H.; Lee, H.; Bastidas, D.; Dean, R. T. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J. Nucl. Med., 1996, 37, 1016-1022.
58. Menda, Y.; Kahn, D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin. Nucl. Med., 2002, 32, 92-96.
59. Blum, J.; Handmaker, H.; Lister-James, J.; Rinne, N. A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest, 2000, 117, 1232-1238.
60. Shah, T.; Kulakiene, I.; Quigley, A. M.; Warbey, V. S.; Srirajaskanthan, R.; Toumpanakis, C.; Hochhauser, D.; Buscombe, J.; Caplin, M. E. The role of 99mTc-depreotide in the management of neuroendocrine tumours. Nucl. Med. Commun., 2008, 29, 436-440.
61. Antunes, P.; Ginj, M.; Zhang, H.; Waser, B.; Baum, R. P.; Reubi, J. C.; Maecke, H. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 982-993.
62. Baum, R.; Schmucking, M.; Wortmann, R.; Muller, M.; Zhernosekov, K.; Rosch, F. Receptor PET/CT using the Ga-68 labelled somatostatin analog DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical experience in 140 patients. Nuklearmedizin, 2005, 44, A57.
63. Hofmann, M.; Oei, M.; Boerner, A. R.; Maecke, H.; Geworski, L.; Knapp, W. H.; Krause, T. Comparison of Ga-68-DOTATOC and Ga-68-DOTANOC for radiopeptide PET. Nuklearmedizin, 2005, 44, A58.
64. Win, Z.; Rahman, L.; Murrell, J.; Todd, J.; Al-Nahhas, A. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 506.
65. Traub, T.; von Guggenberg, E.; Kendler, D.; Eisterer, W.; Bale, R.; Dobrozemsky, G.; Gabriel, M.; Decristoforo, C.; Virgolini, I. First experience with Ga-68-DOTA-lanreotide PET in tumor patients. Nuklearmedizin, 2005, 44, A198.
66. Hofmann, M.; Maecke, H.; Borner, R.; Weckesser, E.; Schoffski, P.; Oei, L.; Schumacher, J.; Henze, M.; Heppeler, A.; Meyer, J.; Knapp, H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur. J. Nucl. Med., 2001, 28, 1751-1757.
67. Win, Z.; Al-Nahhas, A.; Rubello, D.; Gross, M. D. Somatostatin receptor PET imaging with Gallium-68 labeled peptides. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 244-250.
68. Meisetschlager, G.; Poethko, T.; Stahl, A.; Wolf, I.; Scheidhauer, K.; Schottelius, M.; Herz, M.; Wester, H. J.; Schwaiger, M. J. Nucl. Med., 2006, 47, 566-573.
69. Schottelius, M.; Poethko, T.; Herz, M.; Reubi, J. C.; Kessler, H.; Schwaiger, M.; Wester, H. J. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin. Cancer Res., 2004, 10, 3593-3606.
70. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27-31.
71. Mousa, S. A. Mechamism of angiogensis in vascular disorders: Potential therapeutic targets. Drugs Future, 1998, 23, 51-60.
72. Mousa, S. A. Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications. Emerging Ther. Targets, 2000, 4, 389-395.
73. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 2000, 6, 389-395.
74. Bogler, O.; Mikkelsen, T. Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation. Cancer J., 2003, 9, 205-213.
75. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 2002, 29, 15-18.
76. Hwang, R.; Varner, J. The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am., 2004, 18, 991-1006 vii.
77. Ellis, L. M.; Liu, W.; Fan, F.; Jung, Y. D.; Reinmuth, N.; Stoeltzing, O.; Takeda, A.; Akagi, M.; Parikh, A. A.; Ahmad, S. Synopsis of angiogenesis inhibitors in oncology. Oncology (Williston Park), 2002, 16, 14-22.
78. Jin, H.; Varner, J. Integrins: Roles in cancer development and as treatment targets. Br. J. Cancer, 2004, 90, 561-565.
79. Kumar, C. C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets, 2003, 4, 123-131.
80. Brooks, P. C.; Clark, R. A.; Cheresh, D. A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 1994, 264, 569-571.
81. Ruoslahti, E.; Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science, 1987, 238, 491-497
82. Ivaska, J.; Heino, J. Adhesion receptors and cell invasion: Mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol. Life Sci., 2000, 57, 16-24.
83. Hynes, R. O. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell, 1992, 69, 11-25.
84. Felding-Habermann, B.; O'Toole, T. E.; Smith, J. W.; Fransvea, E.; Ruggeri, Z. M.; Ginsberg, M. H.; Hughes, P. E.; Pampori, N.; Shattil, S. J.; Saven, A.; Mueller, B. M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA, 2001, 98, 1853-1858.
85. Reinmuth, N.; Liu, W.; Ahmad, S. A.; Fan, F.; Stoeltzing, O.; Parikh, A. A.; Bucana, C. D.; Gallick, G. E.; Nickols, M. A.; Westlin, W. F.; Ellis, L. M. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res., 2003, 63, 2079-2087.
86. Zhao, Y.; Bachelier, R.; Treilleux, I.; Pujuguet, P.; Peyruchaud, O.; Baron, R.; Clement-Lacroix, P.; Clezardin, P. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res., 2007, 67, 5821-5830.
87. Eliceiri, B. P.; Cheresh, D. A. The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J. Clin. Invest., 1999, 103, 1227-1230.
88. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715.
89. Horton, M. A. The alpha v beta 3 integrin "vitronectin receptor". Int. J Biochem. Cell Biol., 1997, 29, 721-725.
90. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J.; Carroll, R. S.; Nikas, D. C.; Strasser, J. F.; Villani, R.; Cheresh, D. A.; Black, P. M. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery, 2001, 49, 380-389.
91. Gurrath, M.; Muller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem., 1992, 210, 911-921.
92. Pfaff, M.; Tangemann, K.; Muller, B.; Gurrath, M.; Muller, G. et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem., 1994, 269, 20233-20238
93. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding to integrins. J. Biol. Chem., 2000, 275, 21785-21788.
94. Suehiro, K.; Smith, J. W.; Plow, E. F. The ligand recognition specificity of beta3 integrins. J. Biol. Chem., 1996, 271, 10365-10371.
95. Albelda, S. M.; Mette, S. A.; Elder, D. E.; Stewart, R.; Damjanovich, L.; Herlyn, M.; Buck, C. A. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res., 1990, 50, 6757-6764.
96. Felding-Habermann, B.; Mueller, B. M.; Romerdahl, C. A.; Cheresh, D. A. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. J. Clin. Invest., 1992, 89, 2018-2022.
97. Falcioni, R.; Cimino, L.; Gentileschi, M. P.; D'Agnano, I.; Zupi, G.; Kennel, S. J.; Sacchi, A. Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes. Exp. Cell Res., 1994, 210, 113-122.
98. Meitar, D.; Crawford, S. E.; Rademaker, A. W.; Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol., 1996, 14, 405-414.
99. Gasparini, G.; Brooks, P. C.; Biganzoli, E.; Vermeulen, P. B.; Bonoldi, E.; Dirix, L. Y.; Ranieri, G.; Miceli, R.; Cheresh, D. A. Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin. Cancer Res., 1998, 4, 2625-2634.
100. Sengupta, S.; Chattopadhyay, N.; Mitra, A.; Ray, S.; Dasgupta, S.; Chatterjee, A. Role of alphavbeta3 integrin receptors in breast tumor. J. Exp. Clin. Cancer Res., 2001, 20, 585-590.
101. Zitzmann, S.; Ehemann, V.; Schwab, M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res., 2002, 62, 5139-5143.
102. Weber, W. A.; Haubner, R.; Vabuliene, E.; Kuhnast, B.; Wester, H. J.; Schwaiger, M. Tumor angiogenesis targeting using imaging agents. Q. J. Nucl. Med., 2001, 45, 179-182.
103. Costouros, N. G.; Diehn, F. E.; Libutti, S. K. Molecular imaging of tumor angiogenesis. J. Cell Biochem. Suppl., 2002, 39, 72-78.
104. Van De Wiele, C.; Oltenfreiter, R.; De Winter, O.; Signore, A.; Slegers, G.; Dierckx, R. A. Tumour angiogenesis pathways: Related clinical issues and implications for nuclear medicine imaging. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29, 699-709.
105. Liu, S.; Robinson, S. P.; Edwards, D. S. Integrin alphaV beta3 directed radiopharmaceutical for tumor imaging. Drugs Future, 2003, 28, 551-564.
106. Liu, S.; Robinson, S. P.; Edwards, D. S. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Top. Curr. Chem., 2005, 252, 117-153.
107. Haubner, R.; Wester, H. J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des., 2004, 10, 1439-1455.
108. Chen, X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev. Med. Chem., 2006, 6, 227-234.
109. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alphaVbeta3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl., 1997, 36, 1374-1389.
110. Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-1164.
111. Clezardin, P. Recent insights into the role of integrins in cancer metastasis. Cell Mol. Life Sci., 1998, 54, 541-548.
112. Aumailley, M.; Gurrath, M.; Muller, G.; Calvete, J.; Timpl, R. et al. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 1991, 291, 50-54.
113. Gurrath, M.; Muller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem., 1992, 210, 911-921.
114. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. P. Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin alphaVbeta3 Antagonists. J. Am. Chem. Soc, 1996, 118, 7461-7472.
115. Gottschalk, K. E.; Kessler, H. The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction. Angew. Chem. Int. Ed. Engl., 2002, 41, 3767-3774.
116. Bach II, A. C.; Espina, J. R.; Jackson, S. A.; Stouten, P. F. W.; Duke, J. L.; Mousa, S. A.; DeGrado, W. F. Type II' to Type I -Turn Swap Changes Specificity for Integrins. J. Am. Chem. Soc., 1996, 118, 293-294.
117. Muller, G.; Gurrath, M.; Kessler, H. Pharmacophore refinement of gpIIb/ IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides. J. Comput. Aided Mol. Des., 1994, 8, 709-730.
118. Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem., 1993, 268, 1066-1073.
119. Dechantsreiter, M. A.; Planker, E.; Matha, B.; Lohof, E.; Holzemann, G.; Jonczyk, A.; Goodman, S. L.; Kessler, H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem., 1999, 42, 3033-3040
120. Eskens, F. A.; Dumez, H.; Hoekstra, R.; Perschl, A.; Brindley, C. et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur. J. Cancer, 2003, 39, 917-926.
121. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D. et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2005, 2, e70.
122. Friess, H.; Langrehr, J. M.; Oettle, H.; Raedle, J.; Niedergethmann, M.; Dittrich, C.; Hossfeld, D. K.; Stoger, H.; Neyns, B.; Herzog, P.; Piedbois, P.; Dobrowolski, F.; Scheithauer, W.; Hawkins, R.; Katz, F.; Balcke, P.; Vermorken, J.; van Belle, S.; Davidson, N.; Esteve, A. A.; Castellano, D.; Kleeff, J.; Tempia-Caliera, A. A.; Kovar, A.; Nippgen, J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.
123. Beekman, K. W.; Colevas, A. D.; Cooney, K.; Dipaola, R.; Dunn, R. L.; Gross, M.; Keller, E. T.; Pienta, K. J.; Ryan, C. J.; Smith, D.; Hussain, M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design. Clin. Genitourin Cancer, 2006, 4, 299-302.
124. Nabors, L. B.; Mikkelsen, T.; Rosenfeld, S. S.; Hochberg, F.; Akella, N. S.; Fisher, J. D.; Cloud, G. A.; Zhang, Y.; Carson, K.; Wittemer, S. M.; Colevas, A. D.; Grossman, S. A. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol., 2007, 25, 1651-1657.
125. Garanger, E.; Boturyn, D.; Dumy, P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med. Chem., 2007, 7, 552-558.
126. MacDonald, T. J.; Stewart, C. F.; Kocak, M.; Goldman, S.; Ellenbogen, R. G.; Phillips, P.; Lafond, D.; Poussaint, T. Y.; Kieran, M. W.; Boyett, J. M.; Kun, L. E. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J. Clin. Oncol., 2008, 26, 919-924.
127. Xiong, J. P.; Stehle, T.; Diefenbach, B.; Zhang, R.; Dunker, R.; Scott, D. L.; Joachimiak, A.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science, 2001, 294, 339-345.
128. Xiong, J. P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science, 2002, 296, 151-155.
129. Thumshirn, G.; Hersel, U.; Goodman, S. L.; Kessler, H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry, 2003, 9, 2717-2725.
130. Wester, H. J.; Kessler, H. Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? J. Nucl. Med., 2005, 46, 1940-1945.
131. Boturyn, D.; Coll, J. L.; Garanger, E.; Favrot, M. C.; Dumy, P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J. Am. Chem. Soc., 2004, 126, 5730-5739.
132. Liu, S.; Hsieh, W. Y.; Kim, Y. S.; Mohammed, S. I. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug. Chem., 2005, 16, 1580-1588.
133. de Visser, M.; Verwijnen, S. M.; de Jong, M. Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy. Cancer Biother. Radiopharm., 2008, 23, 137-157
134. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des., 2006, 12, 2723-2747.
135. Psimadas, D.; Fani, M.; Zikos, C.; Xanthopoulos, S.; Archimandritis, S. C.; Varvarigou, A. D. Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3 (CO)3]+ and evaluation for early angiogenesis detection in cancer. Appl. Radiat. Isot., 2006, 64, 151-159.
136. Lee, Y. S.; Jeong, J. M.; Kim, H. W.; Chang, Y. S.; Kim, Y. J.; Hong, M. K.; Rai, G. B.; Chi, D. Y.; Kang, W. J.; Kang, J. H.; Lee, D. S.; Chung, J. K.; Lee, M. C.; Suh, Y. G. An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c(RGDyK). Nucl. Med. Biol., 2006, 33, 677-683.
137. Decristoforo, C.; Faintuch-Linkowski, B.; Rey, A.; von Guggenberg, E.; Rupprich, M.; Hernandez-Gonzales, I.; Rodrigo, T.; Haubner, R. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl. Med. Biol., 2006, 33, 945-952.
138. Jia, B.; Shi, J.; Yang, Z.; Xu, B.; Liu, Z.; Zhao, H.; Liu, S.; Wang, F. 99mTc-labeled cyclic RGDfK dimer: Initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Bioconjug. Chem., 2006, 17, 1069-1076.
139. Liu, S.; Edwards, D. S.; Ziegler, M. C.; Harris, A. R.; Hemingway, S. J.; Barrett, J. A. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug. Chem., 2001, 12, 624-629.
140. Mitra, A.; Coleman, T.; Borgman, M.; Nan, A.; Ghandehari, H.; Line, B. R. Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. J. Control Rel., 2006, 114, 175-183.
141. Dijkgraaf, I.; Kruijtzer, J. A.; Frielink, C.; Soede, A. C.; Hilbers, H. W.; Oyen, W. J.; Corstens, F. H.; Liskamp, R. M.; Boerman, O. C. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists. Nucl. Med. Biol., 2006, 33, 953-961.
142. Dijkgraaf, I.; Kruijtzer, J. A.; Liu, S.; Soede, A. C.; Oyen, W. J.; Corstens, F. H.; Liskamp, R. M.; Boerman, O. C. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 267-273
143. Dijkgraaf, I.; Rijnders, A. Y.; Soede, A.; Dechesne, A. C.; van Esse, G. W.; Brouwer, A. J.; Corstens, F. H.; Boerman, O. C.; Rijkers, D. T.; Liskamp, R. M. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes. Org. Biomol. Chem., 2007, 5, 935-944.
144. Dijkgraaf, I.; Liu, S.; Kruijtzer, J. A.; Soede, A. C.; Oyen, W. J.; Liskamp, R. M.; Corstens, F. H.; Boerman, O. C. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl. Med. Biol., 2007, 34, 29-35.
145. Dijkgraaf, I.; Kruijtzer, J. A.; Frielink, C.; Corstens, F. H.; Oyen, W. J.; Liskamp, R. M.; Boerman, O. C. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int. J. Cancer, 2007, 120, 605-610.
146. Zhang, X.; Chen, X. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent. Appl. Radiat. Isot., 2007, 65, 70-78.
147. Alves, S.; Correia, J. D.; Gano, L.; Rold, T. L.; Prasanphanich, A.; Haubner, R.; Rupprich, M.; Alberto, R.; Decristoforo, C.; Santos, I.; Smith, C. J. In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). Bioconjug. Chem., 2007, 18, 530-537.
148. Liu, S.; Hsieh, W. Y.; Jiang, Y.; Kim, Y. S.; Sreerama, S. G.; Chen, X.; Jia, B.; Wang, F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug. Chem., 2007, 18, 438-446.
149. Wu, Z.; Li, Z. B.; Chen, K.; Cai, W.; He, L.; Chin, F. T.; Li, F.; Chen, X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J. Nucl. Med., 2007, 48, 1536-1544.
150. Li, Z. B.; Wu, Z.; Chen, K.; Chin, F. T.; Chen, X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug. Chem., 2007, 18, 1987-1994.
151. Li, Z. B.; Cai, W.; Cao, Q.; Chen, K.; Wu, Z.; He, L.; Chen, X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J. Nucl. Med., 2007, 48, 1162-1171.
152. Li, Z. B.; Chen, K.; Chen, X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1100-1108.
153. Edwards, D.; Jones, P.; Haramis, H.; Battle, M.; Lear, R.; Barnett, D. J.; Edwards, C.; Crawford, H.; Black, A.; Godden, V. 99mTc-NC100692 - a tracer for imaging vitronectin receptors associated with angiogenesis: A preclinical investigation. Nucl. Med. Biol., 2008, 35, 365-375.
154. Roed, L.; Oulie, I.; Knuttel, T.; Toft, K. G.; Hustvedt, S. O.; Skotland, T. Metabolism in rats of NC100692, an RGD-peptide for imaging of angiogenesis. J. Pharm. Biomed. Anal., 2008, 47, 164-169.
155. Indrevoll, B.; Kindberg, G. M.; Solbakken, M.; Bjurgert, E.; Johansen, J. H.; Karlsen, H.; Mendizabal, M.; Cuthbertson, A. NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging. Bioorg. Med.Chem. Lett., 2006, 16, 6190-6193.
156. Hua, J.; Dobrucki, L. W.; Sadeghi, M. M.; Zhang, J.; Bourke, B. N.; Cavaliere, P.; Song, J.; Chow, C.; Jahanshad, N.; van Royen, N. Buschmann, I.; Madri, J. A.; Mendizabal, M.; Sinusas, A. J. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation, 2005, 111, 3255-3260.
157. Lindsey, M. L.; Escobar, G. P.; Dobrucki, L. W.; Goshorn, D. K.; Bouges, S.; Mingoia, J. T.; McClister, D. M., Jr.; Su, H.; Gannon, J.; MacGillivray, C.; Lee, R. T.; Sinusas, A. J.; Spinale, F. G. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H232-H239.
158. Bach-Gansmo, T.; Danielsson, R.; Saracco, A.; Wilczek, B.; Bogsrud, T. V.; Fangberget, A.; Tangerud, A.; Tobin, D. Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692. J. Nucl. Med., 2006, 47, 1434-1439.
159. Glaser, M.; Morrison, M.; Solbakken, M.; Arukwe, J.; Karlsen, H.; Wiggen, U.; Champion, S.; Kindberg, G. M.; Cuthbertson, A. Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug. Chem., 2008, 19, 951-957.
160. ] Del Gatto, A.; Zaccaro, L.; Grieco, P.; Novellino, E.; Zannetti, A. et al. Novel and selective alpha(v)beta3 receptor peptide antagonist: Design, synthesis, and biological behavior. J. Med. Chem., 2006, 49, 3416-3420.
161. de Tullio, P.; Delarge, J.; Pirotte, B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr. Med. Chem., 1999, 6, 433-455.
162. Escherich, A.; Lutz, J.; Escrieut, C.; Fourmy, D.; van Neuren, A. S.; Muller, G.; Schafferhans, A.; Klebe, G.; Moroder, L. Peptide/ benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors. Biopolymers, 2000, 56, 55-76.
163. Herranz, R. Cholecystokinin antagonists: Pharmacological and therapeutic potential. Med. Res. Rev., 2003, 23, 559-605.
164. Reubi, J. C.; Schaer, J. C.; Waser, B. Cholecystokinin(CCK)-A and CCK-B/ gastrin receptors in human tumors. Cancer Res., 1997, 57, 1377-1386.
165. Berna, M. J.; Jensen, R. T. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr. Top. Med. Chem., 2007, 7, 1211-1231.
166. Baldwin, G. S.; Shulkes, A. CCK receptors and cancer. Curr. Top. Med. Chem., 2007, 7, 1232-1238.
167. Reubi, J. C. Targeting CCK receptors in human cancers. Curr. Top. Med. Chem., 2007, 7, 1239-1242.
168. Reubi, J. C.; Macke, H. R.; Krenning, E. P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med., 2005, 46 Suppl 1, 67S-75S.
169. Laverman, P.; Behe, M.; Oyen, W. J.; Willems, P. H.; Corstens, F. H.; Behr, T. M.; Boerman, O. C. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug. Chem., 2004, 15, 561-568.
170. Wank, S. A. Cholecystokinin receptors. Am. J. Physiol., 1995, 269, G628-646.
171. Mansi, R.; Tesauro, D.; De Capua, A.; Fattorusso, R.; Caraco, C.; Aloj, L.; Benedetti, E.; Morelli, G. Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization. Biopolymers, 2004, 76, 527-534
172. Aloj, L.; Panico, M.; Caraco, C.; Del Vecchio, S.; Arra, C.; Affuso, A.; Accardo, A.; Mansi, R.; Tesauro, D.; De Luca, S.; Pedone, C.; Visentin, R.; Mazzi, U.; Morelli, G.; Salvatore, M. In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. Cancer Biother. Radiopharm., 2004, 19, 93-98.
173. Aloj, L.; Caraco, C.; Panico, M.; Zannetti, A.; Del Vecchio, S.; Tesauro, D.; De Luca, S.; Arra, C.; Pedone, C.; Morelli, G.; Salvatore, M. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J. Nucl. Med., 2004, 45, 485-494.
174. D'Andrea, L. D.; Testa, I.; Panico, M.; Di Stasi, R.; Caraco, C.; Tarallo L.; Arra C.; Barbieri A.; Romanelli A.; Aloj L. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m)Tc-tricarbonyl. Biopolymers, 2008, 90, 707-712.
175. Berna, M. J.; Tapia, J. A.; Sancho, V.; Jensen, R. T. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr. Opin. Pharmacol., 2007, 7, 583-592.
176. De Luca, S.; De Capua, A.; Saviano, M.; Della Moglie, R.; Aloj, L.; Tarallo, L.; Pedone, C.; Morelli, G. Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor. Bioorg. Med. Chem., 2007, 15, 5845-5853.
177. De Luca, S.; Saviano, M.; Della Moglie, R.; Digilio, G.; Bracco, C.; Aloj, L.; Tarallo, L.; Pedone, C.; Morelli, G. Chem. Med. Chem., 2006, 1, 997-1006.
178. De Luca, S.; Saviano, M.; Lassiani, L.; Yannakopoulou, K.; Stefanidou, P.; Aloj, L.; Morelli, G.; Varnavas, A. Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes". J. Med. Chem., 2006, 49, 2456-2462.
179. De Luca, S.; Morelli, G. Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling. J. Pept. Sci., 2004, 10, 265-273.
180. De Luca, S.; Ragone, R.; Bracco, C.; Digilio, G.; Aloj, L.; Tesauro, D.; Saviano, M.; Pedone, C.; Morelli, G. A cyclic CCK8 analogue selective for the cholecystokinin type A receptor: Design, synthesis, NMR structure and binding measurements. Chembiochem, 2003, 4, 1176-1187.
181. Morelli, G.; De Luca, S.; Tesauro, D.; Saviano, M.; Pedone, C.; Dolmella, A.; Visentin, R.; Mazzi, U. CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: Synthesis and molecular mechanics calculations. J. Pept. Sci., 2002, 8, 373-381.
182. De Luca, S.; Tesauro, D.; Di Lello, P.; Fattorusso, R.; Saviano, M.; Pedone, C.; Morelli, G. Synthesis and solution characterization of a porphyrin-CCK8 conjugate. J. Pept. Sci., 2001, 7, 386-394.
183. Rovati, A. L.; Casula, P. L.; Da Re, G. [Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)]. Minerva Med., 1967, 58, 3656-3670.
184. Rovati, A. L. Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents. Scand. J. Gastroenterol. Suppl., 1976, 42, 113-118.
185. Makovec, F.; Bani, M.; Cereda, R.; Chiste, R.; Pacini, M. A.; Revel, L.; Rovati, L. A.; Rovati, L. C.; Setnikar, I. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung, 1987, 37, 1265-1268.
186. Setnikar, I.; Bani, M.; Cereda, R.; Chiste, R.; Makovec, F.; Pacini, M. A.; Revel, L. Anticholecystokinin activities of loxiglumide. Arzneimittelforschung, 1987, 37, 1168-1171.
187. Makovec, F.; Peris, W.; Revel, L.; Giovanetti, R.; Mennuni, L.; Rovati, L. C. Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. J. Med. Chem., 1992, 35, 28-38.
188. Revel, L.; Ferrari, F.; Makovec, F.; Rovati, L. C.; Impicciatore, M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur. J. Pharmacol., 1992, 216, 217-224.
189. Makovec, F.; Peris, W.; Frigerio, S.; Giovanetti, R.; Letari, O.; Mennuni, L.; Revel, L. Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. J. Med. Chem., 1996, 39, 135-142.
190. Fontana, M. G.; Donato, F.; Villanacci, V.; Ghirardi, M.; Moneghini, D.; Di Betta, E.; Salerni, B. nhibitory effect of a gastrin receptor antagonist, CR2945, on 1, 2-dimethylhydrazine-induced colorectal cancer in mice. Eur. Surg. Res., 1999, 31, 406-411.
191. Giragossian, C.; Mierke, D. F. Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance. Life Sci., 2003, 73, 705-713.